| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | Chief Financial Officer, Executive Vice President, Legal and Secretary | Common Stock | 717,307 | $2,194,959 | $3.06 | 31 Jan 2025 | Direct |
| Atea Pharmaceuticals, Inc. | Chief Financial Officer, Executive Vice President, Legal and Secretary | Restricted Stock Units | 10,500 | $32,130 | $3.06 | 31 Jan 2025 | Direct |
| Atea Pharmaceuticals, Inc. | Chief Financial Officer, Executive Vice President, Legal and Secretary | Stock Option (Right to Buy) | 200,000 | 31 Jan 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2025 | 6 | -$49,272 | 4 | Chief Financial Officer, Executive Vice President, Legal and Secretary | 04 Feb 2025, 18:00 |
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2024 | 4 | -$60,915 | 4 | Chief Financial Officer, Executive Vice President, Legal and Secretary | 02 Feb 2024, 21:31 |
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2023 | 2 | $0 | 4 | Chief Financial Officer, Executive Vice President, Legal and Secretary | 02 Feb 2023, 17:30 |
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2022 | 1 | $0 | 4 | Chief Financial Officer, Executive Vice President, Legal and Secretary | 02 Feb 2022, 16:15 |